5月29日午前6時(現地5月28日午後5時ET)から米国臨床腫瘍学会（American Society of Clinical Oncology: ASCO）が今年はオンラインで開催されます。今回のSynix Oncology Newsletterでは、Oracle Life Sciencesおよびサイニクスが特に注目しているトピックをお届けします。

ASCO 2020の注目トピック

尿路上皮がん (Urothelial carcinoma)

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.
Abstract #: LBA1

大腸がん(Colorectal cancer)

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study.
Abstract #: LBA4

A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
Abstract #: 4000

非小細胞肺がん (NSCLC)

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Abstract #: LBA5

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
Abstract #: 9504

多発性骨髄腫 (Multiple myeloma)

Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.
Abstract #: 8501

胃がん(Gastric cancer)

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized, phase II, multicenter, open-label study (DESTINY-Gastric01).
Abstract #: 4513